---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-045970"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-20T23:42:11.877078+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neuphoria Q1 update: BNC-210 Phase 3 topline due Q3 2025; cash runway into Q3 2026

## Summary
- Cash runway extends into Q3 2026; no near-term financing risk stated.
- Phase 3 AFFIRM-1 trial of BNC-210 for social anxiety disorder on track for topline readout in Q3 2025.
- Partnered α7 nAChR PAM MK-1167 (Merck) in Phase 2 for Alzheimer's disease.
- Phase 2b SYMPHONY trial for BNC-210 in PTSD planned after positive FDA End-of-Phase 2 meeting.

## SEC filing metadata
- accession: 0001213900-25-045970
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390025045970/0001213900-25-045970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390025045970/ea0242929-8k_neuphoria.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-045970
- JSON: https://secwatch.observer/filing/0001213900-25-045970.json
- Plain text: https://secwatch.observer/filing/0001213900-25-045970.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.